Synapse - Works

Results (115783)

Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups

Meeting Abstract

Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
Blood (2022)

Fulltext@MSK | Save

Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study

Meeting Abstract

Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
Blood (2022)

Fulltext@MSK | Save

Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 trial

Meeting Abstract

Nooka, A. K.; Cohen, A.; Lee, H. C.; Badros, A. Z.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E.; more...
Blood (2022)

Fulltext@MSK | Save

Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)

Meeting Abstract

Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S.; Brown, J. R.; Mato, A. R.; more...
Blood (2022)

Fulltext@MSK | Save

The mutagenic impact of radiotherapy in multiple myeloma

Meeting Abstract

Diamond, B.; Poos, A. M.; Ziccheddu, B.; Maclachlan, K. H.; Zhang, Y.; Usmani, S.; Boyle, E. M.; Davies, F. E.; Morgan, G. J.; Landgren, O.; more...
Blood (2022)

Fulltext@MSK | Save

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience

Meeting Abstract

Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
Blood (2022)

Fulltext@MSK | Save

Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Mohan, S. R.; Chase, C. C.; Berdeja, J. G.; Karlin, L.; Belhadj, K.; Perrot, A.; Moreau, P.; Touzeau, C.; Chalopin, T.; Lesokhin, A. M.; more...
Blood (2022)

Fulltext@MSK | Save

Patterns of childbirth in women with myeloproliferative neoplasms

Meeting Abstract

Landtblom, A. R.; Andersson, T. M. L.; Johansson, A. L. V.; Lundberg, F. E.; Samuelsson, J.; Björkholm, M.; Hultcrantz, M.
Blood (2022)

Fulltext@MSK | Save

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS/AML

Meeting Abstract

Wheeler, E. C.; Martin, B.; Doyle, W.; Gorelov, R.; Donahue, M.; Jann, J. C.; Abdel-Wahab, O.; Taylor, J.; Seiler, M.; Buonamici, S.; more...
Blood (2022)

Fulltext@MSK | Save

Transfusion patterns during early follow-up predict overall survival independently of IPSS-M in patients with myelodysplastic syndromes

Meeting Abstract

Creignou, M.; Bernard, E.; Crowther, M.; Tranberg, A.; Ejerblad, E.; Nilsson, L.; Garelius, H.; Antunovic, P.; Hellström-Lindberg, B. E.; Lorenz, F.; more...
Blood (2022)

Fulltext@MSK | Save